New therapeutic agent proves more effective treatment for advanced prostate cancer
Friday, January 6, 2017 - 14:31
in Health & Medicine
Medical researchers have demonstrated that lutetium-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy of patients with metastatic castration-resistant prostate cancer.